Age-standardized pancreatic cancer mortality rates have not improved since 2010-2014.
-
-
Meta-analysis finds OS benefit in stage III disease and non-surgical patients.
-
First and only drug approved for patients receiving platinum/etoposide or topotecan chemotherapy.
-
Authors call findings an historic milestone.
-
Survival and response did not improve vs pembrolizumab alone.
-
5-year follow-up data from pembrolizumab and nivolumab trials.
-
Results from the ITACA study.
-
Study finds that patients with ECOG PS ≥2 fare significantly worse.
-
The complete resection rate was comparable to the rate in a preoperative chemotherapy trial.
-
Results from the CHRYSALIS study.
-
UK study finds that current guidelines recommending X-ray first lead to a delayed diagnosis.
-
An open-label, single-arm, phase 2a clinical trial from the MiST1 study group.
-
The study shows that the fossil fuel component of PM2.5 contributes a large global mortality burden, and supports switching to renewable energy.
-
Findings from the phase 3 CONFIRM trial.